• Users Online: 742
  • Print this page
  • Email this page


 
 
Table of Contents
REVIEW
Year : 2018  |  Volume : 7  |  Issue : 1  |  Page : 6-14

Diabetes mellitus and male infertility


Division of Medical Physiology, Faculty of Medicine and Health Sciences, Stellenbosch University, Tygerberg, South Africa

Date of Submission22-Oct-2017
Date of Decision30-Oct-2017
Date of Acceptance20-Nov-2017
Date of Web Publication19-Dec-2017

Correspondence Address:
S Omolaoye Temidayo
Division of Medical Physiology, Faculty of Medicine and Health Sciences, Stellenbosch University, Francie van Zijl Drive, Tygerberg 7505
South Africa
S du Plessis Stefan
Division of Medical Physiology, Faculty of Medicine and Health Sciences, Stellenbosch University, Francie van Zijl Drive, Tygerberg 7505
South Africa
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/2305-0500.220978

Rights and Permissions
  Abstract 


Infertility is prevalent in about 10%-25% of couples in their reproductive age, analogous to 60-80 million infertile couples globally. Of these infertility cases, 10%-30% are exclusively attributed to a problem of the male. Several diseases have been implicated as contributors to deteriorating male fertility and diabetes mellitus (DM) is included. DM, a chronic non-communicable disease, has been considered as one of the most appreciable health threats, as it affects 9% (422 million) of the world’s population as of 2014. It is characterised by hyperglycaemia, which can result from the inability of the pancreatic β-cells to secrete insulin or from the target tissue becoming insensitive to insulin. DM has been reported to influence male reproductive function through diverse pathways and mechanisms. The adverse effects of reactive oxygen species and successive development of oxidative stress that occur due to DM have been investigated and implicated by several studies. The products of non-enzymatic glycosylation are reported to be widely distributed in the reproductive tract of diabetic men. Additionally, DM has been implicated to impair the processes of male sexual acts. Data reported in this review were extracted from PubMed, Google Scholar, Science Direct and Scopus with diabetes and male infertility as the key search words. In light of the aforementioned, the aim of this review is to provide brief background information on DM as well highlight and explain the likely mechanisms of male fertility which DM impacts.

Keywords: Diabetes mellitus, Male infertility, Diabetic neuropathy, Oxidative stress, Reactive oxygen species, Advanced glycated end products


How to cite this article:
Temidayo S O, Stefan S d. Diabetes mellitus and male infertility. Asian Pac J Reprod 2018;7:6-14

How to cite this URL:
Temidayo S O, Stefan S d. Diabetes mellitus and male infertility. Asian Pac J Reprod [serial online] 2018 [cited 2019 Aug 25];7:6-14. Available from: http://www.apjr.net/text.asp?2018/7/1/6/220978




  1. Introduction Top


Diabetes mellitus (DM) is an embodiment of diverse metabolic disorders marked by chronic hyperglycaemia that can result from lack in insulin synthesis and secretion or reduced sensitivity of tissues to insulin[1]. In present day societies, DM represents one of the most noticeable health perils and its prevalence is increasing swiftly. In 2014, the World Health Organization reported that 422 million people have DM, connoting a 60% global increase relative to 2002[2]. The World Health Organization previously projected that the number will rise to about 300 million by 2025[1]. Our calculation however, showed that the projected value of DM for 2025 has already been surpassed by 28.9% in 2014. In recent years, the views that DM has inconsequential effects on male reproductive function have been questioned by conclusive data from various studies.

Male infertility describes a male’s inefficiency to cause fertilization in a fertile female over a period of 12 months of consistent and unprotected intercourse[3]. It is estimated that 56% of infertile couples of childbearing age seek medical help[4]. Amidst these couples, 10%-30% of infertility cases are attributed exclusively to a problem of the male and another 15%-30% of cases showed significant anomalies in both partners[5]. Studies on prevalence of infertility in DM male partners of infertile couples revealed diminished sperm motility and increased abnormal sperm morphology[6],[7]. Additionally, the increased production of highly potent free radicals and subsequent production of advanced glycation end products (AGEs) as well as an upsurge in the expression of receptor for AGE have been reported in DM[8],[9]. These molecules are likewise implicated amongst other pathology of diabetic neuropathy (DN)[10]. With the data available, there is no uncertainty that DM is responsible for various pathological and biochemical modifications that reduce male fertility[11].

The aim of this review is to provide an abrupt background on DM and introduce its relationship to male infertility. It will as well make specific reference of the possible mechanisms via which DM elicits its impact on the male reproductive system. Data reported in this review were extracted from PubMed, Google Scholar, Science Direct and Scopus with diabetes and male infertility as the key search words.


  2. Overview of DM Top


DM prevalence has increased substantially in the last three decades, and has been ranked to be the 7th cause of death in human race[2]. Hyperglycaemia is a known effect of uncontrolled diabetes and consequently can lead to damage to various systems and tissues, especially the nerves and blood vessels[12]. Diverse pathogenic processes are included in the development of DM ranging from pancreatic β-cells autoimmune destruction with insulin insufficiency to abnormalities that causes resistance to insulin action[13]. The fundamental effect of insulin loss or insulin ineffectiveness on glucose homeostasis is the inefficient uptake and usage of glucose by glucose dependent cells, resulting in hyperglycaemia.

In the healthy state, the presence of insulin causes the stimulation of the glucose transporters (GLUTs), allowing glucose to bind to the extracellular portion of these transporters, which results in the translocation of the protein, thus having rapid glucose diffusion into the cell[14],[15]. In DM, due to decreased insulin, there is dysregulation of the processes of glucose metabolism and utilization that concurrently alters the stimulatory effect of insulin on glucose transporter translocation.

The numerous cases of DM fall into two broad categories that are classified as Type I and Type II . In both types of DM, metabolism of carbohydrates, lipids and protein are impaired.

2.1. Type I DM

Out of 422 million people affected by DM globally, 10% is attributed to Type I DM. About 85% of this population are diagnosed before the age of 20 and 15% of the cases are ascribed to adults (30 years old). It is instigated by injury or cellular-controlled autoimmune destruction of the pancreatic β-cells. Heredity, race or ethnicity, age and gender are some of the associated risk factors that play a role in ascertaining the susceptibility of the insulin producing cells to abrasion. It may develop swiftly over a period of a few days or weeks, following this sequence: (1) decreased insulin; (2) elevated usage of fats for energy and for formation of cholesterol by the liver; (3) reduction of the body’s proteins[16].

2.2. Type II DM

The prevalence and incidence of Type II DM is rapidly increasing throughout the world and it accounts for 90%-95% of those with DM. Type II DM was known to be an adult or old age disease. But in the last few decades, its prevalence has increased among youth, which predicts for higher estimate of occurrence in the future. It occurs as a result of decreased perceptivity of target tissues to the metabolic effects of insulin. Type II DM is also described as a ‘contemporary disease’ because it is caused by lifestyle factors, such as diet and obesity. Ethnicity, environmental exposure and socio-economic factors are also evident risk factors. In comparison to Type I DM, it is correlated with elevated plasma insulin concentrations (hyperinsulinemia). This occurs as compensatory feedback by the pancreatic β-cells for reduced sensitivity of marked tissues to the metabolic effects of insulin. The diminished insulin sensitivity debilitates carbohydrate usage and storage, increasing blood glucose and spurring a compensatory increase in insulin secretion.

It was predicted in 2016 that there would be a 71.5% prevalence increase of Type II DM amidst age 20-79 by 2035, including 6.0% in Africa, 7.1% in Europe, 11.3% in Middle East, 12.3% in North America and Caribbean, 8.2% in South and Central America, 9.4% in South East Asia and 8.4% in Western Pacific[17]. Considering the above futuristic prevalence evaluation, DM will affect more men ahead of and amid their reproductive years.


  3. Impact of diabetes on male fertility Top


Diabetes has been substantiated to have adverse effects on both male and female reproductive function[16],[18] and its impacts can be seen in increased prevalence of infertility[6],[19],[20],[21]. About 90% of diabetics experience upheaval in sexual function, including a decrease in libido, impotence and infertility[22]. Furthermore, diabetic men are vulnerable to different sexual problems, though progressive physical disorders and deteriorative psychological response are contributors[23]. Several studies have investigated and reported different pathologies commonly experienced by diabetic men and have also highlighted the subsequent reproductive defects. Some of the extracted findings highlighting the impacts of DM on male reproductive functions in human and animal models were represented in [Table 1]. Selected mechanisms through which DM impact male reproductive function were summarized in [Figure 1].
Table 1: Findings highlighting impact of DM on male reproductive functions in human and animal models.

Click here to view
Figure 1: Mechanisms through which DM affects male reproductive functions. ↑ = increase, ↓ decrease.

Click here to view


3.1. Effects on spermatogenesis: role of endocrine disorder

Under normal circumstances, the hypothalamus releases gonadotropin releasing hormone, thereby stimulating the anterior pituitary to secrete luteinizing hormone (LH) and follicle stimulating hormone (FSH). LH stimulates the Leydig cells to secrete testosterone and dihydrotestosterone, while FSH stimulates the  Sertoli cells More Details of seminiferous tubules to assist the process of spermatogenesis.

Unarguably, spermatozoa are capable of using glycolysis and/or oxidative phosphorylation in generating energy. They are as well structured to be capable of using external hexoses (glucose, fructose and mannose), and smaller substrates (lactate, citrate amino acids and lipids) for energy production[30]. Though, spermatozoa are known to secret their own insulin, they are however sensitive to hormonal fluctuations[37]. Therefore, deficiency of insulin or insensitivity to insulin in DM alters the endocrine pathway (negative feedback mechanism), resulting in impaired male reproductive function.

Animal studies on induced hyperglycaemia revealed some adverse effects on male reproductive function relative to altered endocrine control [Table 1]. Additionally, decreased Sertoli cell vacuolization[26], decreased sperm production[29],[33],[38],[39],[40], decreased fertility[33],[41], alteration of epididymis morphology and density[39], decreased LH, FSH and testosterone serum levels[42],[43], decreased number of Leydig and Sertoli cells and decreased number of spermatogonia[33] were observed in induced diabetes. The effects of DM on spermatogenesis have not only been shown in animal models, but have also been shown in men [Table 1].

Furthermore, Ballester et al[30] reported a reduction in Leydig cell number and impaired cell function in streptozocin (STZ) induced mice model of DM. The decreased Leydig cell number linked to the decrease in serum LH, which in part explained the stimulatory effects of LH on Leydig cells. This also indicated that the Leydig cells production involving insulin and insulin-like growth factor 1 signal mechanisms is mediated by LH[44],[45]. While the impaired cell function was measured by the loss of tyrosine phosphorylation, as well as decreased expression of GLUT-3 receptors, androgen receptors and insulin-like growth factor 1 receptors[36]. These findings are supported by several other animal studies that investigated the effect of DM on male fertility[35],[39],[46],[47]. Also, DM alters spermatogenesis through an FSH-related mechanism. Insulin deficiency present in Type I DM does not appear to affect spermatogenesis through a direct effect on the epithelium of seminiferous tubules, but instead by an alteration in serum FSH levels[30],[48]. Decreased FSH is followed by a reduction in tubular FSH receptors in STZ induced Type I DM, thus causing a diminished response of the epithelium of the seminiferous tubules to FSH stimulation. Therefore, DM alters spermatogenesis by disrupting the modulating effect of insulin on the regulation of serum FSH levels[30],[48].

Likewise, glucose has been shown to be important for spermatogenesis and the acrosome reaction (AR). This was evidenced when a medium deprived of glucose inhibited the spontaneous AR, which was swiftly restored after the subsequent addition of glucose[49]. These substrates are conveyed into the cell by GLUTs[50].

GLUTs are specific transporters that catalyze the passive diffusion of glucose into the mammalian cells along a concentration gradient. The GLUT family consists of 14 members and can be divided into three groups based on their sequence similarities[51].

GLUT8 belongs to the class 3 transporters and is expressed predominantly in the testis[52],[53]. Research on GLUT8 expression in human spermatozoa revealed its presence in the acrosome and midpiece region of mature spermatozoa[54]. It was also found in the acrosome and midpiece region of mouse mature spermatozoa[55]. While some researches detected GLUT8 in differentiating spermatocytes of the stage 1 type, but not in mature spermatozoa[52]. Glucose transported into the cell is converted to energy, which is needed for spermatogenesis and motility. The disruption of GLUT8 activity caused by decreased insulin resulted in reduced sperm motility and impaired fertilization[56]. This can as well be a result of lower gonadotropin response to gonadotropin releasing hormone in diabetics[44].

3.2. Effect on sperm parameters: role of oxidative stress (OS) and AGEs

Studies have shown that DM induces subtle molecular changes that are essential for sperm quality and function. In a study carried out on 52 diabetic men, semen analysis revealed a significant decrease in sperm motility, including the number of rapid progressive cells[57]. Furthermore, in a comparative study on sperm cryopreservation, semen samples collected from diabetic men showed a significant decrease in sperm parameters when compared to groups of men with autoimmune disorders, kidney diseases, ulcerative colitis and heart diseases[58]. Another study on prevalence of infertility carried out by Delfino et al[7], revealed a significant alteration in sperm kinetic properties and sperm morphology of male diabetic partners. A few more studies also revealed a significant decrease in semen volume, sperm motility and morphology in the semen of diabetic men[25],[59]. All these outcomes are associated to the development of OS.

Effect of DM on male reproductive function can also be explained through the impact of OS, caused by the inequality between reactive oxygen species (ROS) production and antioxidant defence mechanisms[60]. The main origins of ROS in the male reproductive system are known to be the immature spermatozoa and leukocytes[60],[61]. Additionally, mechanisms that involve repeated mild changes in cellular metabolism may result in tissue damage within a brief occurrence of hyperglycaemia. An enormous bulk of data give priority to certain metabolic pathways as being dominant contributors to hyperglycaemic induced cell damage, e.g. elevated glycolysis, glucose autoxidation, increased polyol pathway flux, increased AGE formation, activation of protein kinase C isoforms and increased hexosamine pathway flux[62],[63]. It has been shown that excessive production of O2- by mitochondria in hyperglycaemia is the trigger propel these pathways. Excessive production of O2- momentously inhibits glyceraldehyde-3-phosphate dehydrogenase activity, which in turn activates all the pathways of hyperglycaemic damage by diverting upstream glycolytic metabolites to these pathways[62]. Furthermore, when the highly potent ROS exceeds the seminal antioxidant defence ability, many cascades of reactions will occur, which can lead to sperm DNA damage and mitochondrial DNA fragmentation, then altered sperm parameters and subsequently male infertility.

In OS, there is excessive production of NO- which is detrimental to sperm motility. NO- may react with O2- or H2O2 to form ONOO- or OH-, which will cause oxidation of sperm membrane lipids and thiol proteins[45]. It can also cause a decreased ATP levels, thereby affecting the kinematics of spermatozoa.

The high polyunsaturated fatty acids contents in the sperm plasma membrane are susceptible to ROS, its invasion thereof, leads to lipid peroxidation[64]. Lipid peroxidation occurs in 3 stages that are initiation, propagation, and termination. During initiation, free radicals react with fatty acid chains to form the lipid peroxyl radical. Peroxyl radicals in turn react with fatty acids to produce free radicals and the reaction is thus propagated. In termination, the two radicals react with each other which lead to lipid break down[64]. Furthermore, oxidation of sugar by OH- has been shown to be the main cause of DNA strand breaks. Oxidative damage can further cause base degradation, DNA fragmentation, and cross-linking of proteins. The proportion of DNA strand break is increased in the sperm of infertile diabetic men[9]. Apoptosis, also regarded as programmed cell death, can be instigated by ROS-induced oxidative damage. High levels of ROS alter integrity of mitochondrial membrane[65],[67],[68], resulting in mitochondria DNA (mtDNA) damage and subsequently affects sperm functions negatively.

Elevated ROS production has also been implicated in the generation of AGEs. AGEs are products of non-enzymatic reaction between sugar and the amino groups of proteins, lipids and DNA under hyperglycaemic conditions[69],[70]. AGEs can alter the normal functioning of macromolecules directly, by generating ROS independently, or indirectly, by activating the receptors for advanced glycated end products (RAGE)[71]. AGEs may play a key role in instigating harm and further act as mediator of damage to reproductive system of diabetic men[72].

RAGE is a ligand binding receptor that increases cellular dysfunction in inflammatory disorders such as DM. RAGE is expressed at low levels in normal tissues. However, in diseased conditions such as DM, its increased expression leads to tissue damage[73],[74]. Immunohistochemistry on the testes, epididymis and spermatozoa of 21 diabetic men revealed the wide distribution of RAGE in their reproductive tracts as compared to non-diabetics[24]. An increased prevalence of immunoreactive cells was revealed in the seminiferous epithelium in the testes of diabetic men and sections of the epididymis displayed various degrees of RAGE immunoreactivity. Increased RAGE expression was also found in the spermatozoa acrosomal cap of these men, as determination of the specific location of RAGE was examined during different stages of the AR[72]. It therefore suggests a major role for glycation processes in sperm nDNA damage and cellular damage[24],[72].

Furthermore, it has been shown that seminal plasma has important antioxidant systems that can supply the spermatozoa with a defensive environment against OS[45]. However, it was demonstrated that diabetic men have significantly lower seminal total antioxidant capacity (TAC) levels compared to their non-diabetic counterparts. This was supported by another study that showed that seminal TAC has an effect on male fertility and that increased ROS levels leads to low TAC levels[75]. The reduced TAC level in DM is consistent with higher malonaldehyde levels, which suggests a possible role for AGEs in instigating lipid peroxidation levels.

3.3. Diabetic neuropathy

DN is one of the most prevalent complications of DM. It has been reported to affect about 50% of patients with Type I and Type II DM. It can be categorized into autonomic neuropathy and peripheral neuropathy because of its effect on either autonomic or peripheral nervous systems. Both neuropathies results from microvascular dysfunction which can affect the autonomic nervous system (ANS), leading to autonomic neuropathy and can as well impair peripheral nerves causing peripheral neuropathy. Various pathogenic pathways involved in the development of DN and subsequent damage of the male reproductive function were summarized in [Figure 2]. Since the ANS is involved in the regulation of sexual response cycle, impairment thereof by DN can result in reduced sexual response, erectile dysfunction (ED) and retrograde ejaculation[76].
Figure 2: Pathogenic pathways of DN leading to male reproductive function impairment.
NAD=nicotinamide adenine dinucleotide; NADH= reduced nicotinamide adenine dinucleotide; PKC= Protein kinase C. ↑ = increase, ↓ = decrease.


Click here to view


3.3.1. Reduced sexual response

Male sexual response is a result of physical or psychological stimulation which leads to vasodilation and subsequent increased blood flow into the penis. Low libido has been reported to be associated with DM and that it worsens with progressive diabetic state[77]. The reduced sexual response/libido can be related to the physical and psychological susceptibility to deterioration in DM. For instance, Fairburn et al[77] reported an absence of pumping sensation that usually follow ejaculation in over a third of diabetic subjects in their study, with these patients describing semen flowing from their erect or drooping penis’ either at or prior to orgasm.

3.3.2. ED

ED is rampant in millions of men, and has been reported to be more prevalent amongst diabetic men. However, ED’s prevalence depends on variant factors, such as the population reviewed, as well as the definition and methods used[78]. For instance, it was reported that 41.3% of adult men (above 18 years old) in France have ED, 33.2% in Brazil and 41.8% in China[79]; 18.0%-48.0% among middle-aged men in Germany[80] and about 50.0% of aging diabetic men (aged 56-85) have ED in the United States[81].

Usually, neurotransmitters, especially NO are released either from the penile nerve endings or endothelium during normal sexual activity, which triggers the relaxation of the cavernosa arteries and the surrounding smooth muscles. This in turn, promotes an increase in penile arterial blood flow, thereby causing an erection. However, diabetic men have impairment in both endothelium dependent smooth muscles and autonomic mechanism that mediate the relaxation of corpora cavernosa[37]. In addition, endothelial dysfunction reflects the loss of NO activity and biosynthesis at the endothelial level, thus leading to ED[82],[83].

3.3.3. Retrograde ejaculation

The emptying of semen in the prostatic urethra results in various reflex actions controlled by sensory nerves from the prostatic urethra. This excites centres in the sacral and lumbar regions of the spinal cord, which then transmits impulses to autonomic and somatic pathways, thereby causing ejaculation. However in DM, retrograde ejaculation occurs due to ANS impairment and subsequent loss of constriction by the external urethral sphincter and loss of other reflex actions involved in ejaculation. Retrograde ejaculation can be defined as the retro-influx of semen into the bladder rather than emptying into the anterior urethra[84]. This can result in the subject experiencing the pumping sensation associated with ejaculation without semen emerging from the penis. Urine collected immediately after ejaculation in these men appears cloudy and the diagnosis of retrograde ejaculation can be confirmed by the numerous spermatozoa in a post-orgasmic urine sample.


  4. Treatment of male infertility caused by diabetes Top


Once an individual has been identified as having fertility related issues due to diabetic complications, treatment should be aimed at treating the disease through amelioration of the underlying cause and subsequently treating the consequences.

4.1. Treatment of diabetes

Treatment of DM focuses on controlling the blood glucose levels without causing hypoglycaemia.

4.1.1. Treating Type I DM

Effective treatment of Type I DM requires administration of sufficient exogenous insulin to maintain glucose metabolisms and also prevent hyperglycaemia. Insulin present in several forms, such as short acting insulin and protein derivative precipitated insulin. The half-life of short acting insulin is 3-8 h, while that of the protein derivatives is 10-48 h[16]. However, treatment should be given with an individualized pattern.

4.1.2. Treating Type Π DM

Management of Type II DM can be accomplished through a strict adherence to healthy lifestyle, diet control, exercise, weight loss and the use of suitable medication in an attempt to reverse insulin resistance. Examples of prescribed drugs for Type II DM are metformin and thiazolidinediones. Metformin works by improving the sensitivity of the body tissues to insulin. Thiazolidinediones make the body’s tissues more sensitive to insulin, while sulfonylureas and meglitinides stimulate the pancreas to secret more insulin.

4.2. Treating the consequences

4.2.1. Antioxidant therapy

Antioxidants operate by arresting the oxidative chain reaction, removing, or reducing the formation of ROS[85]. Hughes et al[86] reported a significant protection of a media containing ascorbic acid (600 μmol/L), alpha-tocopherol (30 and 60 μmol/L), and urate (400 μmol/L) from sperm DNA damage by the non-enzymatic antioxidants during an in vitro fertilization (IVF) procedure. Studies on antioxidant treatment of OS related male infertility reported an improvement of the sperm quality and greater assisted reproductive technology (ART) procedures success rate[87],[88],[89],[90], but antioxidant therapy still remains highly debated and controversial.

4.2.2. ART

Infertility can be reduced in diabetic men with ED or retrograde ejaculation through intra cytoplasmic sperm injection (ICSI) or IVF. Spermatozoa of diabetic men with ED can be obtained via testicular biopsy. Since ICSI-IVF requires at least one sperm, the sperm retrieved can be injected into the female gamete for fertilization. The fertilized embryo can then be transferred inside the uterus.

Also, ICSI-IVF can as well be applied to treatment of diabetic men with retrograde ejaculation. This can be achieved by recovering the spermatozoa from the post ejaculatory urine of these men. Nakolettos et al[54] advised that retrograde ejaculation resistant to long term medication can be managed using the ART, following an outcome of 51.2% fertilization rate amongst their study subjects.

4.2.3. Treating diabetic neuropathy

The aim of managing reduced sexual response, ED and retrograde ejaculation, is to help reduce infertility and also aid the affected to enjoy their sexual activities irrespective of the limits set by the diseased. The treatment can be focused on physical, psychological and surgical treatment as well as medication. Physical treatment improves the subject’s general state of health by changing any reversible physical activity contributing to the sexual problem. Psychological treatment is that primary and secondary psychological reactions contributing to the problem should be tackled. Surgical treatment means surgical management of ED includes implantation of penile prostheses and penile vascular regeneration. Surgical procedure to correct retrograde ejaculation can be done by reconstructing the bladder vesical sphincter[91]. Medication refers to drugs commonly used to manage ED that are Avanafil (Stendra), Sildenafil (Viagra), Tadalafil (Cialis) and Vardenafil (Levitra, Staxyn). All these work by relaxing the smooth muscles and boosting vasodilation, thereby making it easier to achieve and maintain erection.


  5. Conclusion Top


DM has been implicated in the impairment of male fertility. Studies have revealed the different mechanisms involved in this pathology. The mechanisms include endocrine disorder, alteration in GLUT8 activity, OS development, AGEs formation and occurrence of DN. It is important that endocrinologists and physicians educate their patients on the possible impact of DM on male fertility, while reproductive endocrinologists should carefully consider the impact of DM as part of their strategies for fertility treatment.

Conflict of interest statement

The authors declare that they don’t have any conflict of interest.



 
  References Top

1.
World Health Organization (WHO). The cost of diabetes. 2002; fs236. [Online] Available from: www.who.intlmediacentre/factsheets/fs236/en.2002.   Back to cited text no. 1
    
2.
World Health Organization. Global status report on non-communicable diseases. Geneva; 2014. [Online] Available from: http://apps.who.int/iris/ bitstream/10665/204871/1/9789241565257_eng.pdf [Accessed on 9th November 2017].  Back to cited text no. 2
    
3.
World Health Organization. Infertility definitions and terminology. [Online] Available from: www.who.int/reproductivehealth/topics/infertility/definitions/en/ [Accessed on 9th November 2017].  Back to cited text no. 3
    
4.
Boivin J, Bunting L, Collins JA, Nygren KG. International estimates of infertility prevalence and treatment-seeking: Potential need and demand for infertility medical care. Hum Reprod 2007; 22(6): 1506-1512.  Back to cited text no. 4
    
5.
Skakkebaek NE, Jorgensen N, Main KM. Is human fecundity declining? Int J Androl 2006; 29: 2-11.  Back to cited text no. 5
    
6.
Li W, Zheng H, Bukuru J, De Kimpe N. Natural medicines used in the traditional Chinese medical system for therapy of diabetes mellitus. J Ethnopharmacol 2004; 92(1): 1-21.  Back to cited text no. 6
    
7.
Delfino M, Imbrogno N, Elia J, Capogreco F, Mazzilli F. Prevalence of diabetes mellitus in male partners of infertile couples. Minerva Urol Nefrol 2007; 59(2): 131-135.  Back to cited text no. 7
    
8.
Ceriello A. Oxidative stress and glycemic regulation. Metabolism 2002; 49(2 Suppl 1): 27-29.  Back to cited text no. 8
    
9.
Singh VP, Bali A, Singh N, Jaggi AS. Advanced glycation end products and diabetic complications. Korean J Physiol Pharmacol 2014; 18(1): 1-4.  Back to cited text no. 9
    
10.
Alves MG, Martins AD, Rato L, Moreira PI, Socorro S, Oliveira PF. Molecular mechanisms beyond glucose transport in diabetes-related male infertility. Biochim Biophys Acta (Biochimica et Biophysica Acta) 2013; 1832(5): 626-635.  Back to cited text no. 10
    
11.
Rehman K, Beshay E, Carrier S. Diabetes and male sexual function. J Sex Reprod Med 2001; 1: 29-33.  Back to cited text no. 11
    
12.
Vanstone M, Rewegan A, Brundisini F, Dejean D, Giacomini M. Patient perspectives on quality of life with uncontrolled type 1 diabetes mellitus: A systematic review and qualitative meta-synthesis. Ont Health Technol Assess Ser 2015; 15(17): 1-29.  Back to cited text no. 12
    
13.
Buren J, Liu HX, Jensen J, Eriksson JW. Dexamethasone impairs insulin signalling and glucose transport by depletion of insulin receptor substrate-1, phosphatidylinositol 3-kinase and protein kinase B in primary cultured rat adipocytes. Eur J Endocrinol 2002; 146(3): 419-429.  Back to cited text no. 13
    
14.
Kandror KV, Pilch PF. Compartmentalization of protein traffic in insulin-sensitive cells. Am J Physiol 1996; 271: e1-e14.  Back to cited text no. 14
[PUBMED]    
15.
Deng D, Sun P, Yan C, Ke M, Jiang X, Xiong L, et al. Molecular basis of ligand recognition and transport by glucose transporters. Nature 2015; 526(7573): 391-396.  Back to cited text no. 15
    
16.
Arthur CG, Hall J. Guyton and Hall textbook of medical physiology. 12nd ed. [Online] Available from: https://www.elsevier.com/books/guyton-and-hall-textbook-of-medical-physiology/hall/978-0-8089-2400-5 [Accessed on 9th November 2017].  Back to cited text no. 16
    
17.
Giel N. Epidemiology of type 2 diabetes. [Online] Available from: https://doi.org/10.14496/dia.3104287123.18 [Accessed on 9th November 2017].  Back to cited text no. 17
    
18.
American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care 2014; 37(Suppl 1): S81-90.  Back to cited text no. 18
[PUBMED]    
19.
Bener A, Al-Ansari AA, Zirie M, Al-Hamaq AO. Is male fertility associated with type 2 diabetes mellitus? Int Urol Nephrol 2009; 41(4): 777-784.  Back to cited text no. 19
    
20.
Du Plessis SS, Cabler S, McAlister DA, Sabanegh E, Agarwal A. The effect of obesity on sperm disorders and male infertility. Nat Rev Urol 2010; 7(3): 153-161.  Back to cited text no. 20
    
21.
Fedele D. Therapy insight: Sexual and bladder dysfunction associated with diabetes mellitus. Nat Clin Pract Urol 2005; 2(6): 282-290.  Back to cited text no. 21
    
22.
Corona G, Giorda CB, Cucinotta D, Guida P, Nada E. Sexual dysfunction at the onset of type 2 diabetes: The interplay of depression, hormonal and cardiovascular factors. J Sex Med 2014; 11(8): 2065-2073.  Back to cited text no. 22
    
23.
McMahon CG. Ejaculatory disorders. In: Male Sexual Function, editor. Current clinical urology. New York: Humana Press Inc; 2006, p. 447-466.  Back to cited text no. 23
    
24.
Mallidis C, Agbaje I, Rogers D, Glenn J, McCullough S, Atkinson AB, et al. Distribution of the receptor for advanced glycation end products in the human male reproductive tract: Prevalence in men with diabetes mellitus. Hum Reprod 2007; 22(8): 2169-2177.  Back to cited text no. 24
    
25.
Agbaje IM, Rogers DA, McVicar CM, McClure N, Atkinson AB, Mallidis C, et al. Insulin dependant diabetes mellitus: Implications for male reproductive function. Hum Reprod 2007; 22(7): 1871-1877.  Back to cited text no. 25
    
26.
Roessner C, Paasch U, Kratzsch J, Glander HJ, Grunewald S. Sperm apoptosis signalling in diabetic men. Reprod Biomed Online 2012; 25(3): 292-299.  Back to cited text no. 26
    
27.
Bhattacharya SM, Ghosh M, Nandi N. Diabetes mellitus and abnormalities in semen analysis. J Obstet Gynaecol Res 2014; 40(1): 167-171.  Back to cited text no. 27
    
28.
Murray FT, Cameron DF, Orth JM, Katovich MJ. Gonadal dysfunction in the spontaneously diabetic BB rat: Alterations of testes morphology, serum testosterone and LH. Horm Metab Res 1985; 17(10): 495-501.  Back to cited text no. 28
    
29.
Cameron DF, Rountree J, Schultz RE, Repetta D, Murray FT. Sustained hyperglycemia results in testicular dysfunction and reduced fertility potential in BBWOR diabetic rats. Am J Physiol 1990; 259(6): e881-889.  Back to cited text no. 29
    
30.
Ballester J, Muñoz MC, Domínguez J, Rigau T, Guinovart JJ, Rodríguez - Gil JE. Insulin - dependent diabetes affects testicular function by FSH - and LH - linked mechanisms. J Androl 2004; 25(5): 706-719.  Back to cited text no. 30
    
31.
Shrilatha B. Early oxidative stress in testis and epididymal sperm in streptozotocin-induced diabetic mice: Its progression and genotoxic consequences. Reprod Toxicol 2007; 23(4): 578-587.  Back to cited text no. 31
    
32.
Vikram A, Tripathi DN, Ramarao P, Jena GB. Intervention of D-glucose ameliorates the toxicity of streptozotocin in accessory sex organs of rat. Toxicol Appl Pharmacol 2008; 226(1): 84-93.  Back to cited text no. 32
    
33.
Jelodar G, Khaksar Z, Pourahmadi M. Endocrine profile and testicular histomorphometry in adult rat offspring of diabetic mothers. J Physiol Sci 2009; 59(5): 377-382.  Back to cited text no. 33
    
34.
Singh S, Malini T, Rengarajan S, Balasubramanian K. Impacts of experimental diabetes and insulin replacement on epididymal secretory products and sperm maturation in albino rats. J Cell Biochem 2009; 108(5): 1094-1101.  Back to cited text no. 34
    
35.
Navarro-Casado L, Juncos-Tobarra MA, Chafer-Rudilla M, Onzoño LÍ, Blazquez-Cabrera JA, Miralles-Garcia JM. Effect of experimental diabetes and STZ on male fertility capacity. Study in rats. J Androl 2010; 31(6): 584-592.  Back to cited text no. 35
    
36.
Mangoli E, Talebi AR, Anvari M, Pourentezari M. Effects of experimentally-induced diabetes on sperm parameters and chromatin quality in mice. Iran J Reprod Med 2013; 11(1): 53-60.  Back to cited text no. 36
    
37.
Carpino A, Rago V, Guido C, Casaburi I, Aquila S. Insulin and IR-β in pig spermatozoa: A role of the hormone in the acquisition of fertilizing ability. Int J Androl 2010; 33(3): 554-562.  Back to cited text no. 37
    
38.
Rama Raju GA, Jaya Prakash G, Murali Krishna K, Madan K, Siva Narayana T, Ravi Krishna CH. Noninsulin-dependent diabetes mellitus: Effects on sperm morphological and functional characteristics, nuclear DNA integrity and outcome of assisted reproductive technique. Andrologia 2012; 44(Suppl 1): 490-498.  Back to cited text no. 38
[PUBMED]    
39.
Soudamani S, Malini T, Balasubramanian K. Effects of streptozotocin-diabetes and insulin replacement on the epididymis of prepubertal rats: Histological and histomorphometric studies. Endocr Res 2005; 31(2): 81-98.  Back to cited text no. 39
    
40.
Amaral S, Moreno AJ, Santos MS, Seiça R, Ramalho-Santos J. Effects of hyperglycemia on sperm and testicular cells of Goto-Kakizaki and streptozotocin-treated rat models for diabetes. Theriogenology 2006; 66(9): 2056-2067.  Back to cited text no. 40
    
41.
McGaw LJ, Steenkamp V, Eloff JN. Evaluation of Athrixia bush tea for cytotoxicity, antioxidant activity, caffeine content and presence of pyrrolizidine alkaloids. J Ethnopharmacol 2007; 110: 16-22.  Back to cited text no. 41
[PUBMED]    
42.
Seethalakshmi L, Menon M, Diamond D. The effect of streptozotocin-induced diabetes on the neuroendocrine-male reproductive tract axis of the adult rat. J Urol 1987; 138(1): 190-194.  Back to cited text no. 42
    
43.
Scarano WR, Messias AG, Oliva SU, Klinefelter GR, Kempinas WG. Sexual behaviour, sperm quantity and quality after short - term streptozotocin - induced hyperglycaemia in rats. Int J Androl 2006; 29(4): 482-488.  Back to cited text no. 43
    
44.
Baccetti B, La Marca A, Piomboni P, Capitani S, Bruni E, Petraglia F, et al. Insulin-dependent diabetes in men is associated with hypothalamo-pituitary derangement and with impairment in semen quality. Hum Reprod 2002; 17(10): 2673-2677.  Back to cited text no. 44
    
45.
Yu T, Robotham JL, Yoon Y. Increased production of reactive oxygen species in hyperglycemic conditions requires dynamic change of mitochondrial morphology. Proc Natl Acad Sci U S A 2006; 103(8): 2653-2658.  Back to cited text no. 45
    
46.
Mora-Esteves C, Shin D. Nutrient supplementation: Improving male fertility fourfold. Semin Reprod Med 2013; 31(4): 293-300.  Back to cited text no. 46
    
47.
Singh S, Malini T, Rengarajan S, Balasubramanian K. Impact of experimental diabetes and insulin replacement on epididymal secretory products and sperm maturation in albino rats. J Cell Biochem 2009; 108(5): 1094-1101.  Back to cited text no. 47
    
48.
Steger RW, Rabe MB. The effect of diabetes mellitus on endocrine and reproductive function. Proc Soc Exp Biol Med 1997; 214(1): 1-11.  Back to cited text no. 48
    
49.
Urner F, Sakkas D. Glucose participates in sperm-oocyte fusion in the mouse. Biol Reprod 1996; 55(4): 917-922.  Back to cited text no. 49
    
50.
Lampiao F, Du Plessis SS. Insulin stimulates GLUT8 expression in human spermatozoa. J Biosci Tech 2010; 1(2): 90-93.  Back to cited text no. 50
    
51.
Scheepers A, Joost HG, Schurmann A. The glucose transporter families SGLT and GLUT: Molecular basis of normal and aberrant function. JPEN J Parenter Enteral Nutr 2004; 28(5): 364-371.  Back to cited text no. 51
    
52.
Schürmann A, Axer H, Scheepers A, Doege H, Joost HG. The glucose transport facilitator GLUT8 is predominantly associated with the acrosomal region of mature spermatozoa. Cell Tissue Res 2002; 307(2): 237-242.  Back to cited text no. 52
    
53.
Gómez O, Romero A, Terrado J, Mesonero JE. Differential expression of glucose transporter GLUT8 during mouse spermatogenesis. Reproduction 2006; 131(1): 63-70.  Back to cited text no. 53
    
54.
Bucci D, Rodriguez - Gil JE, Vallorani C, Spinaci M, Galeati G, Tamanini C. GLUTs and mammalian sperm metabolism. J Androl 2011; 32(4): 348-355.  Back to cited text no. 54
    
55.
Kim ST, Moley KH. The expression of GLUT8, GLUT9a, and GLUT9b in the mouse testis and sperm. Reprod Sci 2007; 14(5): 445-455.  Back to cited text no. 55
    
56.
Verena G, Stefan S, Andrea S, Gunther W, Robert A, Gerhard A, et al. Targeted disruption of Slc2a8 (GLUT8) reduces motility and mitochondrial potential of spermatozoa. Mol Membr Biol 2008; 25(3): 224-235.  Back to cited text no. 56
    
57.
Bhattacharya SM, Ghosh M, Nandi N. Diabetes mellitus and abnormalities in semen analysis. J Obstet Gynaecol Res 2014; 40(1): 167-171.  Back to cited text no. 57
    
58.
Ranganathan PA, Mahran AM, Hallak JO, Agarwal AS. Sperm cryopreservation for men with nonmalignant, systemic diseases: A descriptive study. J Androl 2002; 23(1): 71-75.  Back to cited text no. 58
    
59.
Ali ST, Rakkah NI. Neurophysiological role of sildenafil citrate (Viagra) on seminal parameters in diabetic males with and without neuropathy. Pak J Pharm Sci 2007; 20(1): 36-42.  Back to cited text no. 59
    
60.
Agarwal A, Virk G, Ong C, du Plessis SS. Effect of oxidative stress on male reproduction. World J Mens Health 2014; 32(1): 1-17.  Back to cited text no. 60
    
61.
Leclerc P, de Lamirande E, Gagnon C. Regulation of proteintyrosine phosphorylation and human sperm capacitation by reactive oxygen derivatives. Free Radic Biol Med 1997; 22(4): 643-656.  Back to cited text no. 61
    
62.
Ahmed RG. The physiological and biochemical effects of diabetes on the balance between oxidative stress and antioxidant defense system. Med J Islamic World Acad Sci 2005; 15: 31-42.  Back to cited text no. 62
    
63.
Rolo AP, Palmeira CM. Diabetes and mitochondrial function: Role of hyperglycemia and oxidative stress. Toxicol Appl Pharmacol 2006; 212(2): 167-178.  Back to cited text no. 63
    
64.
Ding GL, Liu Y, Liu ME, Pan JX, GuoMX, Sheng JZ, et al. The effects of diabetes on male fertility and epigenetic regulation during spermatogenesis. Asian J Androl 2015; 17(6): 948-953.  Back to cited text no. 64
    
65.
Doege H, Schürmann A, Bahrenberg G, Brauers A, Joost HG. GLUT8, a novel member of the sugar transport facilitator family with glucose transport activity. J Biol Chem 2000; 275(21): 16275-16280.  Back to cited text no. 65
    
66.
Ibberson M, Uldry M, Thorens B. GLUTX1, a novel mammalian glucose transporter expressed in the central nervous system and insulin-sensitive tissues. J Biol Chem 2000; 275(7): 4607-4612.  Back to cited text no. 66
    
67.
Ibberson M, Riederer BM, Uldry M, Guhl B, Roth J, Thorens B. Immunolocalization of GLUTX1 in the testis and to specific brain areas and vasopressin-containing neurons. Endocrinology 2002; 143(1): 276-284.  Back to cited text no. 67
    
68.
Joost HG, Thorens B. The extended GLUT-family of sugar/polyol transport facilitators: Nomenclature, sequence characteristics, and potential function of its novel members. Mol Membr Biol 2001; 18(4): 247-256.  Back to cited text no. 68
    
69.
Singh R, Barden A, Mori T, Beilin L. Advanced glycation end-products: A review. Diabetologia 2001; 44: 129-146.  Back to cited text no. 69
[PUBMED]    
70.
Unoki H, Bujo H, Yamagishi S, Takeuchi M, Imaizumi T, Saito Y. Advanced glycation end products attenuate cellular insulin sensitivity by increasing the generation of intracellular reactive oxygen species in adipocytes. Diabetes Res Clin Pract 2007; 76: 236-244.  Back to cited text no. 70
[PUBMED]    
71.
Yamagishi S. Advanced glycation end products (AGEs) and their receptor (RAGE) in health and disease. Curr Pharm Des 2008; 14(10): 939.  Back to cited text no. 71
    
72.
Karimi J, Goodarzi MT, Tavilani H, Khodadadi I, Amiri I. Relationship between advanced glycation end products and increased lipid peroxidation in semen of diabetic men. Diabetes Res Clin Pract 2011; 91(1): 61-66..  Back to cited text no. 72
    
73.
Chavakis T, Bierhaus A, Nawroth PP. RAGE (receptor for advanced glycation end products): A central player in the inflammatory response. Microbes Infect 2004; 6(13): 1219-1225.  Back to cited text no. 73
    
74.
Schmidt AM, Yan SD, Yan SF, Stern DM. The multiligand receptor RAGE as a progression factor amplifying immune and inflammatory responses. J Clin Invest 2001; 108(7): 949-955.  Back to cited text no. 74
    
75.
Mahfouz R, Sharma R, Sharma D, Sabanegh E, Agarwal A. Diagnostic value of the total antioxidant capacity (TAC) in human seminal plasma. Fertil Steril 2009; 91(3): 805-811.  Back to cited text no. 75
    
76.
Raskin P, Donofrio PD, Rosenthal NR. Topiramate vs. placebo in painful diabetic neuropathy: Analgesic and metabolic effects. Neurology 2004; 63(5): 865-873.  Back to cited text no. 76
    
77.
Fairburn CG, McCulloch DK, Wu FC. The effects of diabetes on male sexual function. Clin Endocrinol Metab 1982; 11(3): 749-767.  Back to cited text no. 77
    
78.
Thorve VS, Kshirsagar AD, Vyawahare NS, Joshi VS, Ingale KG, Mohite RJ. Diabetes-induced erectile dysfunction: Epidemiology, pathophysiology and management. J Diabetes Complications 2011; 25(2): 129-136.  Back to cited text no. 78
    
79.
Goldstein I, Goren A, Li V, Tang WY, Hassan TA. Erectile dysfunction prevalence, patient characteristics, and health outcomes globally. J Sex Med 2017; 14(5): e298.  Back to cited text no. 79
    
80.
Englert H, Schaefer G, Roll S, Ahlers C, Beier K, Willich S. Prevalence of erectile dysfunction among middle-aged men in a metropolitan area in Germany. Int J Impot Res 2007; 19(2): 183-188.  Back to cited text no. 80
    
81.
McKinlay JB. The worldwide prevalence and epidemiology of erectile dysfunction. Int J Impot Res 2000; 12(Suppl 4): S6-11.  Back to cited text no. 81
[PUBMED]    
82.
Agarwal A, Nandipati KC, Sharma RK, Zippe CD, Raina R. Role of oxidative stress in the pathophysiological mechanism of erectile dysfunction. J Androl 2006; 27(3): 335-347.  Back to cited text no. 82
    
83.
Bivalacqua TJ, Usta MF, Champion HC, Kadowitz PJ, Hellstrom WJ. Endothelial dysfunction in erectile dysfunction: Role of the endothelium in erectile physiology and disease. J Androl 2003; 24(Suppl 6): S17-37.  Back to cited text no. 83
    
84.
Shen JK, Cheriyan SK, Ko EY. Ejaculatory dysfunction: Retrograde ejaculation. In: Aziz N, Agarwal A, editors. The diagnosis and treatment of male infertility. Switzerland: Springer International Publishing AG; 2017, p. 95-111.  Back to cited text no. 84
    
85.
Bansal AK, Bilaspuri GS. Impacts of oxidative stress and antioxidants on semen functions. Vet Med Int 2011. Available on [http://dx.doi.org/10.4061/2011/686137]  Back to cited text no. 85
    
86.
Hughes CM, Lewis SE, McKelvey-Martin VJ, Thompson W. The effects of antioxidant supplementation during Percoll preparation on human sperm DNA integrity. Hum Reprod (Oxford, England) 1998; 13(5): 1240-1247.  Back to cited text no. 86
    
87.
Kessopoulou E, Powers HJ, Sharma KK, Pearson MJ, Russell JM, Cooke ID, et al. A double-blind randomized placebo cross-over controlled trial using the antioxidant vitamin E to treat reactive oxygen species associated male infertility. Fertil Steril 1995; 64(4): 825-831.  Back to cited text no. 87
    
88.
Ourique GM, Saccol EM, Pês TS, Glanzner WG, Schiefelbein SH, Woehl VM, et al. Protective effect of vitamin E on sperm motility and oxidative stress in valproic acid treated rats. Food Chem Toxicol 2016; 95: 159-167.  Back to cited text no. 88
    
89.
Ahmad G, Sharma R, Roychoudhary S, Esteves S, Agarwal A. Efficacy of ascorbic acid in alleviating oxidative stress using in-vitro human sperm model. Fertil Steril 2016; 106(3): e289.  Back to cited text no. 89
    
90.
Wong W, Thomas CM, Merkus JM, Zielhuis GA, Steegers-Theunissen RP. Male factor sub-fertility: Possible causes and impact of nutritional factors. Fertil Steril 2000; 73(3): 435-442.  Back to cited text no. 90
    
91.
Cakiroglu B, Hazar AI, Sinanoglu O, Arda E, Ekici S. Comparison of transurethral incision of the prostate and silodosin in patients having benign prostatic obstruction in terms of retrograde ejaculation. Arch Ital Urol Androl 2017; 89(1): 31-33.  Back to cited text no. 91
    


    Figures

  [Figure 1], [Figure 2]
 
 
    Tables

  [Table 1]


This article has been cited by
1 Cigarette smoking and its toxicological overview on human male fertility—a prospective review
R. Parameswari,T. B. Sridharan
Toxin Reviews. 2019; : 1
[Pubmed] | [DOI]
2 Attenuation of reproductive dysfunction in diabetic male rats with timber cultured Antrodia cinnamomea ethanol extract
Athira Johnson,Shu-Chun Cheng,David Tsou,Zwe-Ling Kong
Biomedicine & Pharmacotherapy. 2019; 112: 108684
[Pubmed] | [DOI]
3 Tempol improves oxidant/antioxidant parameters in testicular tissues of diabetic rats
Hossein Shateri,Akram Ranjbar,Nejat Kheiripour,Hassan Ghasemi,Yasin Pourfarjam,Elahe Habibitabar,Hamid Gholami,Heresh Moridi
Life Sciences. 2019; 221: 65
[Pubmed] | [DOI]
4 The effect of Saurauia vulcani Korth. leaves extract on penile corpus cavernosa microstructure and the quality of sperm in alloxan-induced diabetic mice
S Hutahaean,R D Banjarnahor,P Darsini,S Ilyas,Emita Sabri
Journal of Physics: Conference Series. 2018; 1116: 052030
[Pubmed] | [DOI]
5 Olive leaves extract attenuates type II diabetes mellitus-induced testicular damage in rats: Molecular and biochemical study
Gamal A. Soliman,Abdulaziz S. Saeedan,Rehab F. Abdel-Rahman,Hanan A. Ogaly,Reham M. Abd-Elsalam,Maged S. Abdel-Kader
Saudi Pharmaceutical Journal. 2018;
[Pubmed] | [DOI]



 

Top
 
  Search
 
    Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
    Access Statistics
    Email Alert *
    Add to My List *
* Registration required (free)  

  3. Impact of dia...4. Treatment of ...
  In this article
Abstract
1. Introduction
2. Overview of DM
5. Conclusion
References
Article Figures
Article Tables

 Article Access Statistics
    Viewed3364    
    Printed95    
    Emailed1    
    PDF Downloaded528    
    Comments [Add]    
    Cited by others 5    

Recommend this journal